Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.56)
# 835
Out of 4,876 analysts
83
Total ratings
52.94%
Success rate
22.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintains: In-Line | $3 → $2 | $2.21 | -9.50% | 4 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $46.70 | +111.99% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $15.13 | +197.42% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $9.66 | +24.22% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.12 | +135.85% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.41 | +72.24% | 2 | Dec 11, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $28.49 | +22.85% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $299.51 | +20.20% | 9 | Aug 8, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $438 → $515 | $443.40 | +16.15% | 18 | Aug 2, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $318.25 | -18.30% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.08 | +85.19% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $9.95 | +231.66% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $56.28 | -32.48% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $37.13 | +115.46% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $5.44 | +230.88% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $3.61 | +592.52% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $7.51 | +725.57% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $6.29 | +456.44% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $23.29 | +3.05% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $10.73 | +179.59% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.20 | +212.50% | 1 | Feb 5, 2020 |
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $2.21
Upside: -9.50%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $46.70
Upside: +111.99%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $15.13
Upside: +197.42%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $9.66
Upside: +24.22%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.12
Upside: +135.85%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.41
Upside: +72.24%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $28.49
Upside: +22.85%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $299.51
Upside: +20.20%
Vertex Pharmaceuticals
Aug 2, 2024
Maintains: Outperform
Price Target: $438 → $515
Current: $443.40
Upside: +16.15%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $318.25
Upside: -18.30%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.08
Upside: +85.19%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $9.95
Upside: +231.66%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $56.28
Upside: -32.48%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $37.13
Upside: +115.46%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $5.44
Upside: +230.88%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $3.61
Upside: +592.52%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $7.51
Upside: +725.57%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $6.29
Upside: +456.44%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $23.29
Upside: +3.05%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $10.73
Upside: +179.59%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.20
Upside: +212.50%